VC-backed Y-mAbs Therapeutics goes public
New York and Denver-based Y-mAbs Therapeutics, a developer of cancer treatments, has raised $96 million for its IPO after pricing its 6 million shares at $16 per share. The stock began trading September 21, 2018 on the NASDAQ under the ticker symbol "YMAB." BofA Merrill Lynch and Cowen are the lead underwriers. Y-mAbs Therapeutics Inc' pre-IPO investors included Sofinnova Ventures and Scopia Capital Management.
21 September 2018•2 mins read
